Evaluating the Safety of Myfortic (Mycophenolate Sodium) in Patients With Lupus Nephritis

Inclusion Criteria

• •1. Aged ≥ 20 years and ≤ 75 years at screening.
• •2. Patients with written informed consent form.
• •3. Male or female diagnosed with SLE.
• •4. Confirmed diagnosis of LN by physician. Diagnosis of LN is defined as:
• •a. Kidney biopsy within 1 year, with histological diagnosis of LN (class III/IV/V)
• •5. Laboratory evidence of active nephritis: spot UPCR\>0.5, and/or proteinuria \> 0.5 g/24 hours, and/or greater than 3+ by dipstick, and/or cellular casts.
• •6. Patients with LN who received EC-MPS for the first time. The patients who switched from other treatment and treatment naive patients (did not received any treatment before) can be included in this study.
• •7. Women of childbearing potential must use effective contraception before beginning EC MPS therapy, during therapy, and for six weeks after their last dose of EC MPS.